Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 20 de 151
Filtrar
1.
Clin Oncol (R Coll Radiol) ; 34(12): e505-e514, 2022 12.
Artigo em Inglês | MEDLINE | ID: mdl-35654667

RESUMO

AIMS: Although palliative radiotherapy for gastric cancer may improve some symptoms, it may also have a negative impact due to its toxicity. We investigated whether symptoms improved after radiotherapy with adjustment for the Palliative Prognostic Index (PPI) considering that patients with limited survival tend to experience deterioration of symptoms. MATERIALS AND METHODS: This study was an exploratory analysis of the Japanese Radiation Oncology Study Group study (JROSG 17-3). We assessed six symptom scores (nausea, anorexia, fatigue, shortness of breath, pain at the irradiated area and distress) at registration and 2, 4 and 8 weeks thereafter. We tested whether symptoms linearly improved after adjusting for the baseline PPI. Shared parameter models were used to adjust for potential bias in missing data. RESULTS: The present study analysed all 55 patients enrolled in JROSG 17-3. With time from registration as the only explanatory variable in the model, a significant linear decrease was observed in shortness of breath, pain and distress (slopes, -0.26, -0.22 and -0.19, respectively). Given that the interaction terms (i.e. PPI × time) were not significantly associated with symptom scores in any of the six symptoms, only PPI was included as the main effect in the final multivariable models. After adjusting for the PPI, shortness of breath, pain and distress significantly improved (slope, -0.25, -0.19 and -0.17; P < 0.001, 0.002 and 0.047, respectively). An improvement in fatigue and distress was observed only in patients treated with a biologically effective dose ≤14.4 Gy. CONCLUSION: Shortness of breath, pain and distress improved after radiotherapy. Moreover, a higher PPI was significantly associated with higher symptom scores at all time points, including baseline. In contrast, PPI did not seem to influence the improvement of these symptoms. Regardless of the expected survival, patients receiving radiotherapy for gastric cancer can expect an improvement in shortness of breath, pain and distress over 8 weeks. Multiple-fraction radiotherapy might hamper the improvement in fatigue and distress by its toxicity or treatment burden.


Assuntos
Radioterapia (Especialidade) , Neoplasias Gástricas , Humanos , Prognóstico , Neoplasias Gástricas/complicações , Neoplasias Gástricas/radioterapia , Cuidados Paliativos , Fadiga/etiologia , Dor/etiologia , Dor/radioterapia , Dor/diagnóstico , Dispneia/etiologia , Dispneia/radioterapia
2.
In Vivo ; 33(5): 1499-1505, 2019.
Artigo em Inglês | MEDLINE | ID: mdl-31471398

RESUMO

BACKGROUND/AIM: The mouse vagina exhibits stratified squamous epithelium, which is comprised of multiple cell layers. We previously showed that erbB signaling, induced by epithelial estrogen receptor 1 (ESR1), is required for the initial differentiation of the epithelium. However, the downstream effector that mediates terminal differentiation in the apical layers remains elusive. The contribution of fibroblast growth factor (FGF) to vaginal epithelial cell differentiation was investigated. MATERIALS AND METHODS: Vaginas from wild-type or epithelium-specific Esr1 conditional knockout (cKO) mice were analyzed using immunohistochemistry and quantitative real-time RT-PCR. RESULTS: Of the FGF ligands examined, Fgf22 mRNA was significantly induced following estrogen treatment. Furthermore, FGF downstream signaling, phosphorylated FRS2 and ERK1/2 were exclusively expressed in the apical layers of the vaginal epithelium. No changes in such expression were observed in the Esr1 cKO mice. CONCLUSION: FGF-ERK/MAPK pathway may be a main inducer of terminal differentiation in the mouse vaginal epithelium.


Assuntos
Diferenciação Celular , Células Epiteliais/citologia , Células Epiteliais/metabolismo , Fatores de Crescimento de Fibroblastos/metabolismo , Mucosa/citologia , Mucosa/metabolismo , Vagina , Animais , Biomarcadores , Diferenciação Celular/genética , Feminino , Ligantes , Camundongos , Camundongos Transgênicos , Transdução de Sinais
3.
Anticancer Res ; 39(7): 3487-3492, 2019 Jul.
Artigo em Inglês | MEDLINE | ID: mdl-31262872

RESUMO

BACKGROUND/AIM: Despite intensive chemotherapy, the survival rates for high-risk neuroblastoma, most of which have MYCN amplification, remain low. Overexpression of N-myc oncoprotein promotes expression of cancer-associated properties. We recently found that combination of all-trans retinoic acid (ATRA) with the ß1-integrin-activating peptide TNIIIA2 attenuated cancer-associated properties of neuroblastoma cells through N-Myc degradation. However, ATRA has serious side-effects and there are concerns about late adverse effects. The aim of this study was to examine the effects of the combination of acyclic retinoid (ACR) with TNIIIA2 on neuroblastoma. MATERIALS AND METHODS: The effects of ACR and TNIIIA2 were examined by neuroblastoma cell proliferation and survival assays as well as by using a neuroblastoma xenograft model. The levels of N-Myc and cancer-associated malignant properties were assayed by western blot and colony formation assay, respectively. RESULTS: Combining ACR, which is clinically safe, with TNIIIA2 induced proteasomal degradation of N-Myc and reduction of neuroblastoma cell malignant properties. An in vivo experiment showed therapeutic potential. CONCLUSION: ACR-TNIIIA2 combination treatment may be efficacious and clinical safe chemotherapy for high-risk neuroblastoma.


Assuntos
Antineoplásicos/uso terapêutico , Proteína Proto-Oncogênica N-Myc/metabolismo , Neuroblastoma/tratamento farmacológico , Peptídeos/uso terapêutico , Tenascina/uso terapêutico , Tretinoína/análogos & derivados , Animais , Antineoplásicos/farmacologia , Proliferação de Células/efeitos dos fármacos , Camundongos Endogâmicos BALB C , Camundongos Nus , Neuroblastoma/metabolismo , Neuroblastoma/patologia , Peptídeos/farmacologia , Fenótipo , Tenascina/farmacologia , Tretinoína/farmacologia , Tretinoína/uso terapêutico , Carga Tumoral/efeitos dos fármacos
4.
Int J Oral Maxillofac Surg ; 47(3): 357-365, 2018 Mar.
Artigo em Inglês | MEDLINE | ID: mdl-29150379

RESUMO

Maxillary distraction is increasingly used for the correction of severe maxillary retrusion in patients with cleft lip and palate. However, control of the maxillary movement is difficult, and the need to wear visible distractors for a long period of time causes psychosocial problems. A two-stage surgical approach consisting of maxillary distraction and mandibular setback was developed to overcome these problems. In this study, changes in maxillofacial morphology and velopharyngeal function were examined in 22 patients with cleft lip and palate who underwent this two-stage approach. Lateral cephalograms taken just before the first surgery, immediately after the second surgery, and at completion of the active post-surgical orthodontic treatment were used to examine maxillofacial morphology. Velopharyngeal function was evaluated by speech therapists using a 4-point scale for hypernasality. The average forward movement of the maxilla with surgery at point A was 7.5mm, and the average mandibular setback at pogonion was 8.6mm. The average relapse rate during post-surgical orthodontic treatment was 25.2% for the maxilla and 11.2% for the mandible. After treatment, all patients had positive overjet, and skeletal relapse was covered by tooth movement during postoperative orthodontics. Velopharyngeal function was not changed by surgery. This method can shorten the period during which the distractors have to be worn and reduce the patient burden.


Assuntos
Fenda Labial/cirurgia , Fissura Palatina/cirurgia , Osteotomia Mandibular/métodos , Osteogênese por Distração/métodos , Insuficiência Velofaríngea/cirurgia , Adolescente , Adulto , Cefalometria , Fenda Labial/fisiopatologia , Fissura Palatina/fisiopatologia , Feminino , Humanos , Masculino , Técnicas de Movimentação Dentária , Resultado do Tratamento , Insuficiência Velofaríngea/fisiopatologia
5.
Transplant Proc ; 48(1): 271-4, 2016.
Artigo em Inglês | MEDLINE | ID: mdl-26915883

RESUMO

PURPOSE: Sirolimus (SRL) is used to treat pulmonary lymphangioleiomyomatosis (P-LAM). There is limited evidence that SRL has systemic efficacy for the patients with extrapulmonary lymphangioleiomyomatosis (E-LAM) remaining after lung transplantation (LT) for P-LAM. This report examines the efficacy of SRL treatment for the patient with E-LAM remaining after an LT for P-LAM. CASE SUMMARY: The course of the patient's recovery from an LT for P-LAM was complicated by lymphedema in the left femoral region that was caused by two E-LAM lesions remaining in the left pelvic cavity and in the retroperitoneal area. After the LT was performed, the patient started SRL treatment to reduce the E-LAM lesions. The daily SRL dose, selected based on the standard SRL dose for P-LAM, was initiated at 1 mg/d and was maintained at 2 mg/d. The remaining E-LAM lesions and lymphedema in the left femoral region improved in approximately 9 months after the LT with the administration of both SRL and the standard immunosuppressive therapy used by Okayama University Hospital, including tacrolimus, mycophenolate mofetil, and prednisolone. The SRL and tacrolimus trough concentrations in whole blood were maintained within the therapeutic window for the next 1.5 years after initiation of SRL treatment. The patient experienced no severe adverse events that required discontinuation of the SRL treatment during this time. CONCLUSION: The patients with remaining E-LAM lesions may receive SRL treatment to improve the quality of life after LT for P-LAM as effective therapy in cases where the patient's recovery is complicated by E-LAM lesions.


Assuntos
Imunossupressores/uso terapêutico , Neoplasias Pulmonares/tratamento farmacológico , Transplante de Pulmão , Linfangioleiomiomatose/tratamento farmacológico , Sirolimo/uso terapêutico , Abdome/patologia , Adulto , Feminino , Humanos , Terapia de Imunossupressão/métodos , Neoplasias Pulmonares/patologia , Linfangioleiomiomatose/patologia , Linfangioleiomiomatose/cirurgia , Linfedema/tratamento farmacológico , Linfedema/etiologia , Ácido Micofenólico/análogos & derivados , Ácido Micofenólico/uso terapêutico , Neoplasia Residual , Pelve/patologia , Prednisolona/uso terapêutico , Qualidade de Vida , Tacrolimo/uso terapêutico
6.
Clin Oncol (R Coll Radiol) ; 28(3): 204-8, 2016 Mar.
Artigo em Inglês | MEDLINE | ID: mdl-26537667

RESUMO

AIMS: The results of previous randomised controlled trials suggest that radiation oncologists should consider the presence of neuropathic pain when they prescribe dose fractionations for painful bone metastases. Although validated screening tools for neuropathic pain features are currently available, the prevalence of such features among patients with painful bone metastases is still poorly understood. The purpose of this study was to estimate the prevalence of neuropathic pain features among patients who received palliative radiotherapy for painful bone metastases. MATERIALS AND METHODS: We conducted a cohort survey of consecutive patients who received palliative radiotherapy for painful bone metastases at St Luke's International Hospital between 2013 and 2014. Patients were prospectively assessed before radiotherapy using the validated screening questionnaire to identify neuropathic pain components in Japanese patients. Pain with neuropathic features was prospectively defined using the total score of the seven-item questionnaire and a cut-off score ≥9. The pain response was assessed 2 months after the start of radiotherapy according to the criteria defined by the International Bone Metastases Consensus Working Party. RESULTS: Eighty-seven patients were assessed. Twenty-four per cent of patients (95% confidence interval: 16-35%) were diagnosed as having pain with neuropathic features. On multivariate analysis, no significant correlations were seen between neuropathic pain features and patient characteristics. Sixty-four patients (74%) were assessable 2 months after the start of radiotherapy. Overall response rates were 59% (95% confidence interval: 33-82%) in patients with neuropathic features and 55% (95% confidence interval: 40-70%) in those without such features. CONCLUSIONS: A considerable proportion of the patients were proven to have bone pain with neuropathic features. Further investigations are warranted to validate symptom assessment tools in cooperation with pain distribution and image findings, and to clarify if the presence of neuropathic pain affects the response to palliative radiotherapy.


Assuntos
Neoplasias Ósseas/radioterapia , Fracionamento da Dose de Radiação , Neuralgia/diagnóstico , Radioterapia/efeitos adversos , Adulto , Idoso , Idoso de 80 Anos ou mais , Neoplasias Ósseas/secundário , Feminino , Humanos , Japão/epidemiologia , Masculino , Pessoa de Meia-Idade , Neuralgia/etiologia , Medição da Dor , Cuidados Paliativos , Prevalência , Estudos Prospectivos , Inquéritos e Questionários
7.
Int J STD AIDS ; 24(1): 67-9, 2013 Jan.
Artigo em Inglês | MEDLINE | ID: mdl-23512508

RESUMO

A 33-year-old man was referred to our institution with papillary masses at the urethral meatus and difficulty urinating. Genital examination showed two piercings on the frenulum, which were penetrating the external urethra. Endoscopic examination revealed papillary tumours over the entire circumference of the penile urethra and the piercing site. The tumours were resected transurethrally. Microscopic examination revealed condylomata acuminata. Human papillomavirus types 6 and 66 were detected in the lesions. Retrograde urethral viral infection is rare because of the protection provided by the mucosal immune system. Genital piercing may have facilitated spread of the human papillomavirus into the urethra.


Assuntos
Piercing Corporal/efeitos adversos , Condiloma Acuminado/diagnóstico , Papillomaviridae/isolamento & purificação , Infecções por Papillomavirus/diagnóstico , Obstrução Uretral/etiologia , Adulto , Condiloma Acuminado/terapia , Condiloma Acuminado/virologia , DNA Viral , Eletrocoagulação , Humanos , Masculino , Infecções por Papillomavirus/tratamento farmacológico , Infecções por Papillomavirus/virologia , Reação em Cadeia da Polimerase , Resultado do Tratamento , Doenças Uretrais/tratamento farmacológico , Doenças Uretrais/virologia
8.
Scand J Surg ; 101(4): 283-6, 2012.
Artigo em Inglês | MEDLINE | ID: mdl-23238505

RESUMO

BACKGROUND: Only limited data in the literature about single-incision laparoscopic rectal surgery, because the laparoscopic stapler does not allow low rectal transection without sufficient distal margins from the umbilicus port. We have developed single-incision plus one port laparoscopic anterior resection of the rectum (SILS+1-AR) as a reduced port surgery in which we can utilize the incision for drainage as an additional access route for laparoscopic procedures including the transection the lower rectum. METHODS: A Lap protector (LP) mini was inserted through a 2.5 cm transumbilical incision, and an EZ-access was mounted to LP and three 5-mm ports were placed in EZ-access. A 12 mm port was inserted in right lower quadrant. Almost all the procedures were performed with usual laparoscopic instruments, and the operative procedures were much the same as in usual laparoscopic low anterior resection of the rectum using a flexible 5mm scope. The rectum was transected normally using only one endoscopic linear stapler inserted from the right lower quadrant port. RESULTS: We underwent modified SILS+1-AR in 16 patients with advanced rectal cancer. In all cases, there was no need to extend the skin incision. We transected the lower rectum with one laparoscopic stapler in all six cases. Postoperative follow-up did not reveal any umbilical wound complications or recurrences. CONCLUSIONS: The safety and feasibility of SILS+1-AR for advanced rectal cancer was established in this study. However, further studies are needed to prove the advantages of this procedure to conventional laparoscopic law anterior resection.


Assuntos
Laparoscopia/métodos , Neoplasias Retais/cirurgia , Reto/cirurgia , Idoso , Idoso de 80 Anos ou mais , Feminino , Seguimentos , Humanos , Laparoscopia/instrumentação , Masculino , Pessoa de Meia-Idade , Grampeadores Cirúrgicos , Grampeamento Cirúrgico/instrumentação , Grampeamento Cirúrgico/métodos , Resultado do Tratamento
10.
Clin Exp Allergy ; 39(9): 1404-14, 2009 Sep.
Artigo em Inglês | MEDLINE | ID: mdl-19486034

RESUMO

BACKGROUND: Prostaglandin (PG) D(2) is the major cylooxygenase metabolite released by mast cells upon allergen stimulation, and elicits responses through either the prostanoid DP1 receptor and/or the chemoattractant receptor homologous molecule expressed on T-helper type 2 (Th2) cells (CRTH2/DP2). Experimental evidence suggests that stimulation of one or both these receptors contributes to asthma pathophysiology. OBJECTIVE: The aim of this study was to test the hypothesis that the prostanoid DP1 receptor contributes to asthma pathophysiology by determining the efficacy of an orally active antagonist for this receptor, S-5751, on allergen-induced bronchoconstriction, airway hyperresponsiveness (AHR) and cellular inflammation in the sheep model of asthma. METHODS: PGD(2)-induced cyclic adenosine monophosphate (cAMP) production in platelet-rich plasma was used to establish the in vitro efficacy of S-5751. In vivo, sheep naturally allergic to Ascaris suum were challenged with an aerosolized antigen with and without S-5751 treatment (given 4 days before and for 6 days after the challenge). RESULTS: S-5751 inhibited PGD(2)-induced cAMP production in platelet-rich plasma with an IC(50) value of 0.12 microm. S-5751 at 30 mg/kg, but not at 3 mg/kg, reduced the early bronchoconstriction and inhibited the late bronchoconstriction. AHR and inflammatory cell infiltration in bronchoalveolar lavage fluid at days 1 and 7 were also inhibited with the 30 mg/kg dose. The responses observed with S-5751 at 30 mg/kg were comparable with those with montelukast treatment (0.15 mg/kg, twice a day, intravenous); however, S-5751 did not block inhaled leukotrieneD(4)-induced broncoconstriction. CONCLUSION: Prostanoid DP1 receptor inhibition may represent an alternative target for asthma therapy.


Assuntos
Antiasmáticos/farmacologia , Asma/tratamento farmacológico , Receptores Imunológicos/antagonistas & inibidores , Receptores de Prostaglandina/antagonistas & inibidores , Tiofenos/farmacologia , Acetatos/farmacologia , Alérgenos/toxicidade , Animais , Asma/induzido quimicamente , Asma/metabolismo , Líquido da Lavagem Broncoalveolar , Broncoconstrição/efeitos dos fármacos , AMP Cíclico/metabolismo , Ciclopropanos , Modelos Animais de Doenças , Relação Dose-Resposta a Droga , Feminino , Humanos , Prostaglandina D2/metabolismo , Quinolinas/farmacologia , Receptores Imunológicos/metabolismo , Receptores de Prostaglandina/metabolismo , Sulfetos , Fatores de Tempo
11.
Anat Histol Embryol ; 38(3): 214-8, 2009 Jun.
Artigo em Inglês | MEDLINE | ID: mdl-19469767

RESUMO

The structure of the equine ovary is different from that of other mammals in its extremely large size, the presence of ovarian fossa and the inverted location of its cortex and medulla. A three-dimensional internal structure microscopy (3D-ISM), which consists of a computer-controlled slicer, a CCD camera, a laser disc recorder and a PC, is very useful for the observation of the internal structures in equine ovaries. In addition, the three-dimensional images of follicles and corpus luteum (CL) reconstructed by the segmentation technique can clarify the spatial arrangement in the equine ovary. In this study, to understand the changes in the ovarian internal structures of the mare during the oestrous cycle, the size and numbers of follicles and luteal structures were analysed by 3D-ISM in addition to the concentrations of progesterone (P(4)) and oestradiol-17beta. As a result, many small follicles (<10 mm in diameter) were detected. It was recognized that the luteal structures were distinguished into three types, such as the corpus haemorragicum (CH), which is formed by blood elements at the cavity after ovulation, CL and corpus albican (CA). There were some CHs and CL in the group, which had the concentration of P(4) > 1 ng/ml. CHs were also observed in the group, which had low level of P(4) (P(4) < 1 ng/ml). CAs were found regardless of the P(4) level. In conclusion, 3D-ISM enabled the internal observation of the ovarian structures in detail, and estimation of the stage of the ovarian cycle with complementary physiological information. The findings by 3D-ISM provide basic information for clinical applications.


Assuntos
Corpo Lúteo/ultraestrutura , Estro/fisiologia , Cavalos/anatomia & histologia , Folículo Ovariano/ultraestrutura , Animais , Corpo Lúteo/anatomia & histologia , Estradiol/sangue , Estro/sangue , Feminino , Cavalos/sangue , Cavalos/fisiologia , Processamento de Imagem Assistida por Computador , Imageamento Tridimensional/veterinária , Microscopia/instrumentação , Microscopia/métodos , Microscopia/veterinária , Folículo Ovariano/anatomia & histologia , Progesterona/sangue , Gravação de Videodisco
12.
Osteoporos Int ; 20(1): 53-60, 2009 Jan.
Artigo em Inglês | MEDLINE | ID: mdl-18496639

RESUMO

UNLABELLED: We analyzed 609 women belonging to the JPOS study in a 10-year follow-up survey, to examine the association of osteoporosis with atherosclerosis. Osteoporosis or prevalent vertebral fracture at baseline was associated with increased intima-media thickness of the carotid bifurcation in postmenopausal women, adjusted for age, BMI, and other variables at baseline. INTRODUCTION: Whether low bone mass predicts increased carotid atherosclerosis has not been fully investigated. METHODS: In 2006, we conducted a 10-year follow-up survey of 1,040 women (follow-up rate: 68.6%). We analyzed 609 women > or =50 years old in 2006 without a history of cardiovascular or connective tissue diseases at baseline. BMD and evaluation of vertebral fracture at baseline were used. The intima-media thickness of carotid bifurcation (BIF-IMT) was measured by B-mode ultrasonography in 2006. RESULTS: Adjusted BIF-IMT values of subjects with spine T-score > or =-1, between-2.5 and -1, and <-2.5 or prevalent vertebral fracture were 1.19 mm, 1.34 mm, 1.57 mm, respectively, in women with less than 10 years since menopause (YSM) (n = 159), 1.30 mm, 1.32 mm, 1.53 mm, in women with YSM > or =10 without a history of hypertension at baseline (n = 144) (both with p < 0.05 for linear trend). Those values among no versus prevalent vertebral fracture in women with YSM > or =10 were 1.40 mm, 1.66 mm with p < 0.05 (n = 202). Those associations were independent of age, BMI, total cholesterol, smoking and drinking habits, history of diabetes mellitus, and hypertension (for women with YSM < 10) at baseline. CONCLUSION: Osteoporosis including prevalent vertebral fracture may be associated with carotid atherosclerosis in the first 10 years of postmenopausal women.


Assuntos
Doenças das Artérias Carótidas/complicações , Osteoporose Pós-Menopausa/complicações , Pós-Menopausa/fisiologia , Absorciometria de Fóton , Idoso , Análise de Variância , Artérias Carótidas/diagnóstico por imagem , Doenças das Artérias Carótidas/diagnóstico , Feminino , Seguimentos , Inquéritos Epidemiológicos , Humanos , Japão , Pessoa de Meia-Idade , Osteoporose Pós-Menopausa/diagnóstico , Fraturas da Coluna Vertebral/diagnóstico , Fraturas da Coluna Vertebral/etiologia , Ultrassonografia
13.
Anticancer Res ; 27(4C): 2673-7, 2007.
Artigo em Inglês | MEDLINE | ID: mdl-17695431

RESUMO

UNLABELLED: The aim of this study was to determine the recommended dose of irinotecan in combination with the fixed dose of oral UFT as first-line therapy in patients with advanced or recurrent colorectal cancer, and to evaluate the response rate and overall survival as a phase II study. PATIENTS AND METHODS: Thirteen patients were recruited into a phase I trial. Four doses of irinotecan ranging from 60 to 150 mg/m2/day were administered intravenously on day 1 and day 16 in combination with UFT given orally from day 2 to day 15. In a phase II study, 53 patients received at least one cycle of this therapy. RESULTS: The recommended dose of this combination was determined as irinotecan 120 mg/m2/day and UFT 400 mg/m2/day. Dose-limiting toxicities were neutropenia and prolonged leucopenia. On an intent-to-treat analysis, the response rate in the phase II study was 24.5% (95% confidence interval 13.8% to 38.2%). The median overall survival time was 20.3 months (95% confidence interval, 15.0-22.8 months). Out of 20 patients with stable disease, 17 who received more than 4 cycles of the regimen lived longer than the other 3 patients who received fewer than 3 cycles (p = 0.0353). Hematological adverse events were mainly grade 3/4 neutropenia observed in 6 out of 53 patients. Grade 3 non-hematological toxicities, such as diarrhea, anorexia, nausea/vomiting and alopecia were observed in 6 patients. CONCLUSION: Irinotecan combined with oral UFT was effective and well-tolerated. This regimen may be considered as a first-line therapy for advanced or metastatic colorectal cancer and may result in fairly long survival, even for patients with stable disease.


Assuntos
Protocolos de Quimioterapia Combinada Antineoplásica/efeitos adversos , Protocolos de Quimioterapia Combinada Antineoplásica/uso terapêutico , Neoplasias Colorretais/tratamento farmacológico , Adulto , Idoso , Protocolos de Quimioterapia Combinada Antineoplásica/administração & dosagem , Camptotecina/administração & dosagem , Camptotecina/efeitos adversos , Camptotecina/análogos & derivados , Neoplasias Colorretais/patologia , Esquema de Medicação , Feminino , Humanos , Irinotecano , Masculino , Pessoa de Meia-Idade , Metástase Neoplásica , Recidiva Local de Neoplasia/tratamento farmacológico , Recidiva Local de Neoplasia/patologia , Tegafur/administração & dosagem , Tegafur/efeitos adversos , Uracila/administração & dosagem , Uracila/efeitos adversos
14.
Prostate Cancer Prostatic Dis ; 10(2): 194-201, 2007.
Artigo em Inglês | MEDLINE | ID: mdl-17199134

RESUMO

To compare combination therapy with bicalutamide 80 mg and a luteinizing hormone-releasing hormone agonist (LHRH-A) versus LHRH-A alone in Japanese men with untreated advanced prostate cancer. A total of 205 patients with stage C/D prostate cancer were randomized to either LHRH-A+once-daily oral bicalutamide 80 mg or placebo. Primary study variables have been reported previously. Secondary variables included: time to achieve prostate-specific antigen < or = 4 ng/ml, time-to-treatment failure (TTTF), time-to-disease progression (TTP), overall survival (OS), adverse events and adverse drug reactions. Following combination therapy with bicalutamide 80 mg, there were significant (P<0.001) advantages over LHRH-A alone in terms of TTTF and TTP, but the difference in the interim OS was not statistically significant. First-line combination therapy with bicalutamide 80 mg in Japanese patients with advanced prostate cancer offers significant benefits over LHRH-A alone, with respect to TTTF and TTP. Follow-up for OS continues.


Assuntos
Anilidas/administração & dosagem , Hormônio Liberador de Gonadotropina/agonistas , Gosserrelina/administração & dosagem , Leuprolida/administração & dosagem , Nitrilas/administração & dosagem , Neoplasias da Próstata/tratamento farmacológico , Compostos de Tosil/administração & dosagem , Idoso , Anilidas/antagonistas & inibidores , Método Duplo-Cego , Quimioterapia Combinada , Humanos , Masculino , Nitrilas/antagonistas & inibidores , Compostos de Tosil/antagonistas & inibidores , Resultado do Tratamento
15.
Eur Respir J ; 26(6): 993-1001, 2005 Dec.
Artigo em Inglês | MEDLINE | ID: mdl-16319327

RESUMO

The guinea pig model of cigarette smoke (CS)-induced lung injury is known to exhibit many pathophysiological similarities to chronic obstructive pulmonary disease (COPD), but the expression profiles of inflammatory mediators in the lung are poorly understood. Quantitative real-time RT-PCR was used in this study to investigate the pulmonary expression profiles of cytokine and chemokine mRNA in response to single or repeated CS exposure in guinea pigs. A single CS exposure did not induce obvious inflammatory cell infiltration into the lungs, but it led to significant increases in the mRNA expression of tumour necrosis factor-alpha, interleukin (IL)-1beta, IL-8, and monocyte chemoattractant protein (MCP)-1, and decreases in IL-5 and granulocyte-macrophage colony-stimulating factor. Repeated CS exposure induced many features of COPD, such as marked accumulation of macrophages and neutrophils, augmented protease activities, lung structural alterations and increased airway resistance, accompanied by significant increases in the mRNA expression of IL-1beta and MCP-1 and decreases in IL-2, IL-5, transforming growth factor-beta, and eotaxin. In conclusion, in guinea pigs, inflammatory mediator changes in the lungs following cigarette smoke exposure are largely similar to those reported for smokers and/or chronic obstructive pulmonary disease patients. This model will therefore be useful to further understand the pathogenesis of chronic obstructive pulmonary disease.


Assuntos
Citocinas/metabolismo , Pneumopatias/patologia , Nicotiana/efeitos adversos , Fumaça/efeitos adversos , Doença Aguda , Análise de Variância , Animais , Sequência de Bases , Biomarcadores/análise , Biópsia por Agulha , Líquido da Lavagem Broncoalveolar/química , Líquido da Lavagem Broncoalveolar/citologia , Quimiocinas/metabolismo , Doença Crônica , Modelos Animais de Doenças , Regulação da Expressão Gênica , Cobaias , Imuno-Histoquímica , Pneumopatias/metabolismo , Masculino , Dados de Sequência Molecular , Probabilidade , Doença Pulmonar Obstrutiva Crônica/metabolismo , Doença Pulmonar Obstrutiva Crônica/patologia , RNA Mensageiro/análise , Reação em Cadeia da Polimerase Via Transcriptase Reversa , Fatores de Risco , Sensibilidade e Especificidade , Índice de Gravidade de Doença , Taxa de Sobrevida
16.
Oral Microbiol Immunol ; 20(6): 339-43, 2005 Dec.
Artigo em Inglês | MEDLINE | ID: mdl-16238592

RESUMO

This study investigated the mechanism of protein attachment to the surface of the putative periodontal pathogens Prevotella intermedia and Prevotella nigrescens in artificial gingival crevicular fluid, and ways to increase protein attachment to the bacterial cells. The effects of cations on protein attachment, bacterial adhesion, and hemagglutination were examined, and cation-binding components on both bacterial species were identified. The presence of cations, especially zinc, copper and cerium, increased attachment of human serum proteins to both bacterial species. In contrast, the presence of hydrophobic inhibitors or sugars had little effect. Protein attachment was reduced by heat treatment of the bacterial cells. Pretreatment of bacteria with human serum proteins inhibited adhesion of both species to buccal epithelial cells and hemagglutination. These effects were enhanced by the presence of zinc and copper during pretreatment. Using a chelating column, specific zinc- and copper-binding proteins were identified on the surfaces of both bacterial species.


Assuntos
Aderência Bacteriana/efeitos dos fármacos , Cobre/farmacologia , Hemaglutinação/efeitos dos fármacos , Prevotella intermedia/efeitos dos fármacos , Prevotella nigrescens/efeitos dos fármacos , Zinco/farmacologia , Proteínas de Bactérias/efeitos dos fármacos , Proteínas Sanguíneas/farmacologia , Proteínas de Transporte/efeitos dos fármacos , Cério/farmacologia , Eletroforese em Gel de Poliacrilamida , Células Epiteliais/microbiologia , Líquido do Sulco Gengival/química , Líquido do Sulco Gengival/microbiologia , Temperatura Alta , Humanos , Ligação Proteica/efeitos dos fármacos
17.
Gynecol Endocrinol ; 18(6): 335-40, 2004 Jun.
Artigo em Inglês | MEDLINE | ID: mdl-15497496

RESUMO

Satisfactory results following in vitro fertilization-embryo transfer (IVF-ET) treatments depend on retrieving an appropriate number of mature oocytes without causing the development of ovarian hyperstimulation syndrome (OHSS). The present study was carried out to investigate whether the ovarian reserve is predictable based on the day-3 serum concentration of follicle stimulating hormone (FSH) during the pituitary suppression cycle using a gonadotropin releasing hormone (GnRH) agonist (defined as day-3 FSH) in patients undergoing IVF-ET treatment. Day-3 FSH before the administration of gonadotropin was assessed in 72 IVF-ET cycles from 59 infertile women. The mean+/-SD of day-3 FSH, the total amount of FSH plus human menopausal gonadotropin (hMG) administered, and the total number of oocytes retrieved was 5.5+/-2.6 mIU/ml, 2834.2+/-1236.5 IU and 7.7+/-5.8, respectively. There were significant correlations between day-3 FSH and the total amount of FSH-hMG administered (p < 0.001), and day-3 FSH and total number of oocytes retrieved (p < 0.001). There was a significant difference of day-3 FSH between patients who subsequently conceived (4.4+/-1.3 mIU/ml) and those who did not conceive (6.1+/-2.9 mIU/ml) (p = 0.001). There was also a significant difference of day-3 FSH between patients who developed moderate or severe OHSS (4.5+/-1.2 mIU/ml) and those who did not (5.9+/-2.8 mIU/ml) (p = 0.003). Receiver-operator characteristic curve analysis showed that the significant cut-off point for day-3 FSH for predicting ovarian reserve was 5.25 mIU/ml. These findings indicate that day 3-FSH is usefulfor predicting ovarian reserve during the pituitary suppression cycle using a GnRH agonist in patients undergoing IVF-ET.


Assuntos
Transferência Embrionária , Fertilização in vitro , Hormônio Foliculoestimulante/sangue , Hormônio Foliculoestimulante/farmacologia , Oócitos/efeitos dos fármacos , Indução da Ovulação/métodos , Adulto , Feminino , Hormônio Foliculoestimulante/administração & dosagem , Hormônio Liberador de Gonadotropina/agonistas , Humanos , Infertilidade Feminina , Valor Preditivo dos Testes , Gravidez , Sensibilidade e Especificidade
18.
Clin Exp Immunol ; 136(3): 568-73, 2004 Jun.
Artigo em Inglês | MEDLINE | ID: mdl-15147362

RESUMO

We have reported previously that p95c, a novel 95-kDa cytosolic protein, was the target of autoantibodies in sera of patients with autoimmune hepatic diseases. We studied 30 sera that were shown previously to immunoprecipitate a 95 kDa protein from [(35)S]-methionine-labelled HeLa lysates and had a specific precipitin band in immunodiffusion. Thirteen sera were available to test the ability of p95c antibodies to inhibit nuclear envelope assembly in an in vitro assay in which confocal fluorescence microscopy was also used to identify the stages at which nuclear assembly was inhibited. The percentage inhibition of nuclear envelope assembly of the 13 sera ranged from 7% to 99% and nuclear envelope assembly and the swelling of nucleus was inhibited at several stages. The percentage inhibition of nuclear assembly was correlated with the titre of anti-p95c as determined by immunodiffusion. To confirm the identity of this autoantigen, we used a full-length cDNA of the p97/valosin-containing protein (VCP) to produce a radiolabelled recombinant protein that was then used in an immunoprecipitation (IP) assay. Our study demonstrated that 12 of the 13 (93%) human sera with antibodies to p95c immunoprecipitated recombinant p97/VCP. Because p95c and p97 have similar molecular masses and cell localization, and because the majority of sera bind recombinant p97/VCP and anti-p95c antibodies inhibit nuclear assembly, this is compelling evidence that p95c and p97/VCP are identical.


Assuntos
Autoanticorpos/imunologia , Proteínas de Ciclo Celular/imunologia , Cirrose Hepática Biliar/imunologia , Adenosina Trifosfatases , Reações Antígeno-Anticorpo , Núcleo Celular/imunologia , Feminino , Humanos , Fígado/patologia , Cirrose Hepática Biliar/patologia , Masculino , Microscopia Confocal , Testes de Precipitina , Proteína com Valosina
19.
Int J Oral Maxillofac Surg ; 32(5): 563-5, 2003 Oct.
Artigo em Inglês | MEDLINE | ID: mdl-14759120

RESUMO

Oncocytoma is a rare salivary gland tumour consisting of oncocytes with many hyperplastic mitochondria. It usually occurs in the parotid gland. Because the features of oncocytoma resemble those of other benign and low-grade-malignant salivary gland tumours, clinical diagnosis is often challenging. This report presents the pathologic and imaging findings of an oncocytoma arising in the deep lobe of the left parotid gland in a 66-year-old man. Oncocytoma was diagnosed on the basis of histological, magnetic resonance imaging, and scintigraphic findings. The tumour showed accumulation of technetium-99m pertechnetate and decreased signal intensity on both T1- and T2-weighted magnetic resonance images.


Assuntos
Adenoma Oxífilo/patologia , Neoplasias Parotídeas/patologia , Adenoma Oxífilo/diagnóstico por imagem , Adenoma Oxífilo/cirurgia , Idoso , Humanos , Imageamento por Ressonância Magnética , Masculino , Neoplasias Parotídeas/diagnóstico por imagem , Neoplasias Parotídeas/cirurgia , Cintilografia , Compostos Radiofarmacêuticos , Pertecnetato Tc 99m de Sódio
20.
Kyobu Geka ; 55(9): 799-802, 2002 Aug.
Artigo em Japonês | MEDLINE | ID: mdl-12174627

RESUMO

Coronary artery bypass grafting for patients with ischemic heart disease and hypothyroidism contains many controversies, and chronic renal failure causes perioperative water-electrolyte balance disorders. We experienced a case of unstable angina pectoris combined with hypothyroidism and chronic renal failure successfully treated by off-pump coronary artery bypass grafting (OPCAB). A 68-year-old man with a history of hypothyroidism and chronic renal failure was hospitalized with chest pain. Cardiac catheterisation revealed a 90% stenosis of segment 3, 11 and right ventricular (RV) branch, 75% stenosis of segment 6 and 50% stenosis of segment 5. His thyroid function was normal with orally administered levothyroxine. OPCAB was performed safely with hemodialysis until a day before operation and hemofiltration from a day after operation, and postoperative course was uneventful.


Assuntos
Angina Pectoris/cirurgia , Ponte de Artéria Coronária/métodos , Hipotireoidismo/complicações , Falência Renal Crônica/complicações , Idoso , Angina Pectoris/complicações , Hemofiltração , Humanos , Masculino , Diálise Renal , Resultado do Tratamento , Desequilíbrio Hidroeletrolítico/etiologia
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA